The PMHNP is conducting an Abnormal Involuntary Movement Scale (AIMS) test on her 67-year-old client, who was recently initiated on ziprasidone (Geodon). What does the AIMS test assess?

Choice A reason: Parkinson’s disease is a neurodegenerative disorder characterized by tremors, rigidity, and bradykinesia. While it involves abnormal movements, the AIMS test is not designed to assess Parkinsonian symptoms specifically. Choice B reason: Huntington’s disease is a genetic disorder that causes progressive motor dysfunction, cognitive decline, and psychiatric symptoms. Although it includes involuntary movements, the AIMS test is not used for its diagnosis or monitoring. Choice C reason: Chorea refers to rapid, involuntary movements often seen in Huntington’s disease and other conditions. While chorea may be observed during an AIMS test, the scale is not designed to diagnose chorea itself. Choice D reason: Tardive dyskinesia is a late-onset movement disorder caused by long-term use of antipsychotic medications, including ziprasidone. The AIMS test is specifically designed to detect and monitor symptoms of tardive dyskinesia, such as facial grimacing, tongue movements, and limb jerking.